middle.news
LTR Pharma Teams Up to Develop Rapid-Relief Nasal Spray for Swallowing Disorders
3:00am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
LTR Pharma Teams Up to Develop Rapid-Relief Nasal Spray for Swallowing Disorders
3:00am on Monday 2nd of June, 2025 AEST
Key Points
Collaborative development agreement with Strategic Drug Solutions
OROFLOW® targets Oesophageal Motility Disorders with rapid symptom relief
Non-invasive nasal spray designed for patients with swallowing difficulties
Global OMD market valued at $4.5 billion, projected to reach $8.1 billion by 2034
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Ltr Pharma (ASX:LTP)
OPEN ARTICLE